Data from a late-stage trial of the most advanced of a new class of drugs targeting the hepatitis C virus protease fuel hopes for major improvements in treatment outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Opar, A. Excitement grows for potential revolution in hepatitis C virus treatment. Nat Rev Drug Discov 9, 501–503 (2010). https://doi.org/10.1038/nrd3214
Issue Date:
DOI: https://doi.org/10.1038/nrd3214
This article is cited by
-
Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90β
Acta Pharmacologica Sinica (2023)
-
2010 in reflection
Nature Reviews Drug Discovery (2011)